We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Commissioner Change Won't Affect FDA's Agenda, Observers Say
Commissioner Change Won't Affect FDA's Agenda, Observers Say
October 4, 2005
Acting FDA Commissioner Andrew von Eschenbach is unlikely to have much effect on the agency’s agenda, as the FDA’s existing division heads will continue to drive policy decisions, according to various stakeholders. However, these same sources said the continuous turnover in leadership at the FDA may tarnish the agency’s credibility.